Pyxis Oncology, Inc.

PYXS • Biotechnology

$1.86

▲ +0.02 (+1.30%)

Current price

EarningsLatest report: Jun 30, 2026

WEAK PROFILEWeakConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology

Analysis thesis: Weak historical ratio profile. The current evidence does not support a favorable risk/reward view.

Market Cap

$119.28M

Growth

—

Cash Flow

0/5

Trend

Negative

Evidence

Manageable debt level · 0.35Healthy liquidity · 3.41Negative growth trendWeak profitability

Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 13, 2026, 12:50 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$1.86

Change1.30%

Shares Out63.99M

Market Cap$119.28M

Enterprise Value$104.12M

52W Range1.03 - 5.55

Beta1.32

P/E-1.34

P/S10.81

P/B10.43

P/FCF-1.76

EV/Sales9.43

Price$1.86

Change1.30%

Shares Out63.99M

Market Cap$119.28M

Enterprise Value$104.12M

52W Range1.03 - 5.55

Beta1.32

P/E-1.34

P/S10.81

P/B10.43

P/FCF-1.76

EV/Sales9.43

EV/EBITDA-1.21

EV/FCF-1.53

Earnings Yield-74.39%

FCF Yield-56.94%

Dividend Yield0.00%

Gross Margin82.77%

Oper. Margin-6.09%

Profit Margin-5.75%

Debt/Eq0.35

Current Ratio3.41

Quick Ratio3.41

Target$7.67

Target Upside311.48%

Target Median$8.00

Target Range7.00 - 8.00

Volume1.93M

Avg Volume833.72K

EPS Surprise-0.02

Investment DNA

How strong this company looks for long-term investors

out of 100

Business Quality

Margins, moat, returns

22/100

Financial Strength

Debt, cash, stability

75/100

Growth Potential

Revenue and expansion

20/100

Price Attractiveness

Cheap or expensive today

76/100

Why this score▼

Manageable debt level · 0.35Healthy liquidity · 3.41Negative growth trendWeak profitability

Analyst view

Analyst sentiment and price target

PYXS

Analyst sentiment

Based on 12 analyst votes · 2026-10-20

92/100

Bullish

Hold

Bearish

Price Target

2026-08-14

Low

$6.00

Mean

$6.50

Median

$6.50

High

$7.00

Company Overview

IPO: 10/8/2021

Industry: Biotechnology

P/B i: 10.43

Debt / Equity i: 0.35

Operating Margin: -609.18%

Net Margin: -574.55%

ROE i: -

ROIC: -

Financial Health

Score15 / 20

Debt / Equity: 0.35

Current Ratio: 3.41

Quick Ratio: 3.41

Status: Good

Insider Transactions

Recent executive and insider activity

GordonMD Global Investments LP

Transaction: 06/30/2026

OTHER

Change

+4,900,039

Price

$3.29

Filing

07/10/2026

Type

OTHER

GordonMD Global Investments LP

Transaction: 06/30/2026

OTHER

Change

Price

Not reported

Filing

07/10/2026

Type

OTHER

Dupont Jakob

Transaction: 06/30/2026

SELL

Change

-35,000

Price

$3.06

Filing

07/02/2026

Type

SELL

Insider	Type	Change	Price	Transaction	Filing
GordonMD Global Investments LP	OTHER	+4,900,039	$3.29	06/30/2026	07/10/2026
GordonMD Global Investments LP	OTHER	0	Not reported	06/30/2026	07/10/2026
Dupont Jakob	SELL	-35,000	$3.06	06/30/2026	07/02/2026
Dupont Jakob	SELL	-35,000	$1.60	06/30/2026	07/02/2026
Palani Santhosh	BUY	+45,867	$1.36	03/24/2026	03/25/2026
HUMPHREY RACHEL	BUY	+45,867	$1.36	03/24/2026	03/25/2026
Cline Darren S	BUY	+45,867	$1.36	03/24/2026	03/25/2026
Lewis-Hall Freda C	BUY	+45,867	$1.36	03/24/2026	03/25/2026
Metzger Michael A	BUY	+45,867	$1.36	03/24/2026	03/25/2026
FLAVIN JOHN L	BUY	+45,867	$1.36	03/24/2026	03/25/2026
Wadhane Jitendra	BUY	+262,635	$1.36	03/24/2026	03/25/2026
Wadhane Jitendra	BUY	+109,461	Not reported	03/24/2026	03/25/2026
Dupont Jakob	BUY	+45,867	$1.36	03/24/2026	03/25/2026
HUMPHREY RACHEL	SELL	-13,896	$1.03	04/21/2025	03/25/2026
HUMPHREY RACHEL	SELL	-200	$0.97	04/17/2025	03/25/2026
HUMPHREY RACHEL	SELL	-1,400	$0.97	04/14/2025	03/25/2026
Civik Thomas	BUY	+690,131	$1.49	02/03/2026	02/05/2026
FLAVIN JOHN L	BUY	+36,979	$0.98	03/31/2025	04/02/2025
Connealy Pamela Ann	BUY	+414,163	$0.98	03/31/2025	04/02/2025
Civik Thomas	BUY	+36,979	$0.98	03/31/2025	04/02/2025

About the Company

Pyxis Oncology, Inc.

Pyxis Oncology, Inc. operates as a preclinical biopharmaceutical company focused on developing novel therapeutic approaches to combat various forms of cancer. Its investigational immune-oncology pipeline includes PYX-106, a fully human immunoglobulin G1 (IgG1) antibody designed to target siglec-15, which is being explored for its potential efficacy against thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors. Additionally, PYX-102 is an immune-therapeutic currently under investigation for the treatment of solid tumors. The company's portfolio also features a range of investigational antibody-drug conjugate (ADC) candidates: PYX-201, a novel ADC being developed for NSCLC, breast cancer, and other solid tumors; PYX-202, another novel ADC aimed at small cell lung cancer (SCLC), soft tissue sarcoma, and other solid tumors; and PYX-203, an ADC undergoing evaluation for acute myeloid leukemia and myeloid dysplastic syndrome. Pyxis Oncology was founded in 2018 and is based in Cambridge, Massachusetts.

Source - link

Peers

AVIR CRBU ENTA FHTX HUMA IMRX TNYA VYGR ZURA

Size reflects market cap · color matches the chart line

1Y peer performance

Top performers + selected company

Latest news

Pyxis Oncology (NASDAQ:PYXS) & Precigen (NASDAQ:PGEN) Head to Head Analysis

Precigen (NASDAQ: PGEN - Get Free Report) and Pyxis Oncology (NASDAQ: PYXS - Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, dividends, earnings, institutional ownership and risk. Institutional and Insider Ownership 33.5% of Precigen shares are

Defense World

Pyxis Oncology: Better Runway Is Bullish For MICVO's Remaining R&D

PYXS's main value driver is MICVO. This is an oncology drug candidate that could be useful for killing cancerous cells. MICVO's early data has been promising, but PYXS still has to find an adequate dose that's safe and effective. Fortunately, PYXS's recent raise helps their financing in the near term and should be enough for them to reach important clinical milestones with MICVO.

Seeking Alpha

Pyxis Oncology Announces Closing of Up to $282.6 Million Public Offering

BOSTON, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS or the “Company”), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that it closed its previously announced registered public offering (the "Offering") on October 1, 2026. The Offering generated approximately $110.0 million in upfront gross proceeds, before deducting underwriting discounts and commissions and other offering expenses. The Offering consisted of 36,047,919 shares of common stock at a public offering price of $2.90 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,883,121 shares of common stock at a public offering price of $2.899 per pre-funded warrant, in each case, accompanied by common warrants to purchase an aggregate of 49,310,352 shares of common stock.

GlobeNewsWire

Critical Survey: Pyxis Oncology (NASDAQ:PYXS) versus Inovio Pharmaceuticals (NASDAQ:INO)

Pyxis Oncology (NASDAQ: PYXS - Get Free Report) and Inovio Pharmaceuticals (NASDAQ: INO - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, risk and valuation. Earnings and Valuation This table compares Pyxis

Defense World

Pyxis Oncology Announces Pricing of Up to $282.6 Million Public Offering

BOSTON, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced the pricing of its previously announced registered public offering (the "Offering") of 36,047,919 shares of its common stock, or in lieu of common stock to certain investors, 1,883,121 pre-funded warrants to purchase shares of common stock, and accompanying common warrants to purchase 49,310,352 shares of common stock at an exercise price of $3.50. The combined public offering price for each share of common stock and accompanying common warrant is $2.90, and the combined public offering price for each pre-funded warrant and accompanying common warrant is $2.899 (equal to the combined public offering price per share of common stock and accompanying common warrant, minus $0.001), for expected gross proceeds to Pyxis Oncology of approximately $110 million, before deducting underwriting discounts, commissions and offering expenses. If all of the common warrants and pre-funded warrants are exercised in full, Pyxis Oncology would receive additional gross proceeds of approximately $172.6 million, before deducting applicable expenses.

GlobeNewsWire

Earnings Surprises

Period	Estimate	Actual	Surprise
2026-05-14	-0.35	-0.37	-0.02
2026-03-23	-0.35	-0.29	0.06
2025-11-03	-0.36	-0.35	0.01
2025-08-14	-0.36	-0.3	0.06
2025-05-15	-0.29	-0.35	-0.06
2025-03-18	-0.33	-0.32	0.01
2024-11-12	-0.32	-0.35	-0.03
2024-08-14	-0.33	-0.29	0.04
2024-05-14	-0.27	-0.06	0.21
2024-03-21	-0.49	-0.33	0.16
2023-11-07	-0.57	-0.56	0.01
2023-08-11	-0.66	-0.41	0.25